Tyra Biosciences, Inc. (NASDAQ:TYRA) Shares Sold by Sio Capital Management LLC

Sio Capital Management LLC cut its stake in Tyra Biosciences, Inc. (NASDAQ:TYRA) by 33.2% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 400,870 shares of the company’s stock after selling 199,424 shares during the period. Tyra Biosciences makes up 3.7% of Sio Capital Management LLC’s investment portfolio, making the stock its 8th largest position. Sio Capital Management LLC’s holdings in Tyra Biosciences were worth $9,424,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of TYRA. Walleye Capital LLC boosted its holdings in shares of Tyra Biosciences by 306.5% in the 3rd quarter. Walleye Capital LLC now owns 126,597 shares of the company’s stock valued at $2,976,000 after purchasing an additional 95,451 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new stake in Tyra Biosciences during the third quarter valued at about $593,000. Ally Bridge Group NY LLC increased its stake in Tyra Biosciences by 2.0% during the third quarter. Ally Bridge Group NY LLC now owns 270,075 shares of the company’s stock worth $6,349,000 after acquiring an additional 5,415 shares during the last quarter. FMR LLC raised its holdings in shares of Tyra Biosciences by 0.8% in the 3rd quarter. FMR LLC now owns 3,372,850 shares of the company’s stock worth $79,296,000 after purchasing an additional 26,187 shares during the period. Finally, The Manufacturers Life Insurance Company acquired a new position in shares of Tyra Biosciences in the 3rd quarter valued at about $333,000. 84.14% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Tyra Biosciences

In related news, Director Nina S. Kjellson sold 27,493 shares of the firm’s stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $16.56, for a total value of $455,284.08. Following the sale, the director now directly owns 458,506 shares in the company, valued at $7,592,859.36. This trade represents a 5.66 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Alan Fuhrman acquired 9,500 shares of the business’s stock in a transaction that occurred on Wednesday, October 30th. The shares were bought at an average price of $16.00 per share, for a total transaction of $152,000.00. Following the completion of the purchase, the chief financial officer now owns 12,849 shares of the company’s stock, valued at approximately $205,584. This represents a 283.67 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders have sold 101,050 shares of company stock worth $2,235,492. 15.40% of the stock is owned by insiders.

Tyra Biosciences Trading Up 1.8 %

TYRA stock opened at $16.00 on Friday. The firm has a 50 day simple moving average of $20.27 and a 200-day simple moving average of $19.82. The company has a market capitalization of $809.60 million, a P/E ratio of -9.94 and a beta of 1.08. Tyra Biosciences, Inc. has a twelve month low of $10.60 and a twelve month high of $29.60.

Tyra Biosciences (NASDAQ:TYRA) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.01). On average, research analysts predict that Tyra Biosciences, Inc. will post -1.57 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on TYRA. HC Wainwright dropped their target price on shares of Tyra Biosciences from $32.00 to $30.00 and set a “buy” rating for the company in a research report on Monday, November 11th. Wedbush reissued an “outperform” rating and issued a $28.00 target price on shares of Tyra Biosciences in a research note on Friday, October 25th. Bank of America raised shares of Tyra Biosciences from a “neutral” rating to a “buy” rating and upped their price target for the stock from $22.00 to $31.00 in a research report on Friday, October 18th. Oppenheimer boosted their price objective on Tyra Biosciences from $25.00 to $33.00 and gave the stock an “outperform” rating in a research note on Thursday, September 19th. Finally, Piper Sandler initiated coverage on Tyra Biosciences in a research report on Thursday, August 15th. They set an “overweight” rating and a $33.00 price target on the stock. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Tyra Biosciences currently has a consensus rating of “Buy” and a consensus price target of $31.00.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.